Compare AbCellera Biologics Inc (ABCL) vs Docusign Inc (DOCU) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

DOCU trades at $47.23, up 3.19% with a bullish technical signal. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.09 exceeding estimates. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. The company's partnerships with Perplexity and Slack highlight ongoing innovation in agreement management workflows, supporting future growth prospects amid positive analyst sentiment.

The outlook for DOCU is cautiously optimistic, with a consensus price target of $55.40 suggesting 17% upside. Key opportunities include expanding AI integration and enterprise adoption, but risks involve competitive pressures and reliance on subscription revenue stability. Valuation metrics like a P/E of 30.45 require sustained earnings growth to justify current levels, making execution critical for shareholder returns.